Immunogen (IMGN) Misses Q2 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
ImmunoGen Reports Second Quarter Fiscal Year 2016 Financial Results and Provides Corporate Update
January 29, 2016 6:30 AM ESTConference Call Today at 8:00 am ET
Both ImmunoGens FORWARD I and FORWARD II clinical trials are open for patient enrollment. FORWARD I is designed to support an Accelerated Approval pathway for lead program mirvetuximab soravtansine and FORWARD II assesses this first-in-class folate receptor (FR)-targeting antibody-drug conjugate (ADC) in multiple combination regimens. Bayer has initiated a Phase 2 study designed to support registration of anetumab ravtansine, its mesothelin-targeting ADC. Anetumab ravtansine is the second partner ADC after Roches Kadcyla® with ImmunoGen technology to advance into potential registration testing. Roche expects... More